<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="77401">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02126345</url>
  </required_header>
  <id_info>
    <org_study_id>H-14</org_study_id>
    <nct_id>NCT02126345</nct_id>
  </id_info>
  <brief_title>MASTER SL Clinical Study</brief_title>
  <official_title>A Prospective, Observational, Multi-centre, Cohort Study of the MASTER SL Femoral Stem and the DELTA TT Acetabular Cup in Patients With Degenerative Disease of the Hip</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Limacorporate S.p.a</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Limacorporate S.p.a</source>
  <oversight_info>
    <authority>United Kingdom: Research Ethics Committee</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is:

        -  to generate data to evaluate Orthopaedic Data Evaluation Panel (ODEP) rating to support
           existing short-term clinical results and CE documentation;

        -  to assess the clinical performance of the MASTER SL femoral stem and the DELTA TT
           acetabular cup under standard conditions of use;

        -  to determine any adverse events and assess whether they constitute risks when weighed
           against the intended performance of the device.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Rate of failure</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical progression measured with HHS score, OHS score, Non-Arthritic Hip Score, EQ-5D-5L</measure>
    <time_frame>from baseline to all time-points</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Any undesirable side effects</measure>
    <time_frame>3 and 5 years</time_frame>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Patients Requiring Hip Replacement</condition>
  <arm_group>
    <arm_group_label>MASTER SL</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MASTER SL femoral stem and DELTA TT acetabular cup</intervention_name>
    <arm_group_label>MASTER SL</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients Requiring Hip Replacement
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female â‰¥18 years;

          -  Radiologically confirmed diagnosis of primary osteoarthritis (OA) of the hip and
             suitable for primary total hip replacement;

          -  Life expectancy of &gt;10 years;

          -  Voluntary written Informed Consent obtained.

        Exclusion Criteria:

          -  Prospect for recovery to independent mobility compromised by known coexistent,
             medical problems;

          -  Requiring revision hip replacement;

          -  Loss of abductor musculature, poor bone stock, or poor skin coverage around the hip
             joint;

          -  Previous organ transplant;

          -  Previous hip replacement (resurfacing or THR) on the contra-lateral side within the
             last 6 months;

          -  Previous hip replacement (resurfacing or THR) on the contralateral side and whose
             outcome is achieving an Oxford Hip score &lt;18 points;

          -  Body mass index (kg/m2) exceeds 40;

          -  Active or suspected infection;

          -  Known sensitivity to device materials;

          -  Women of childbearing potential who are pregnant, nursing, or planning to become
             pregnant, and those who do not agree to remain on an acceptable method of birth
             control throughout the entire study period.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Middleton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Bournemouth Hospital NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Bournemouth Hospital NHS Foundation Trust</name>
      <address>
        <city>Bournemouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Robert Middleton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Llandough Cardiff and Vale University Health Board</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Stephen Jones, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Southampton NHS Foundation Trust</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jeremy Latham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 29, 2014</lastchanged_date>
  <firstreceived_date>April 24, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
